Ten more agentic-AI wedges where $100k+ contracts meet real regulatory pain

Asked (summary):

Given current LLMs and long-horizon agents, propose startup ideas with light competition, ACV above $100k, good TAM and large pain.

Asked (follow-up):

“give me 10 more ideas.”

Ten new ideas, ranked, none repeating the original five (grid interconnection, pharma CMC changes, nuclear QA, environmental permit change-control, aircraft AD compliance). Each is backed by two selected evidence rows — 20 rows total from 19 distinct URLs across 17 hosts, a mix of primary/academic, reference and vendor sources. ACV and TAM ranges are founder estimates, not source-reported values.

The map: pain and urgency against competition whitespace

Bubble size is the midpoint of the founder-estimated target ACV range (thousands of dollars per deal); further right means stronger documented pain, further up means less adjacent competition. Blue bubbles are the recommended top five; grey are ideas 6–10, which face more adjacent competition and need a sharper ICP. Hover or tap a bubble for buyer, ACV, TAM and pain proof. Scores are editorial judgments, not measurements.

What the chart cannot say

Transmission ROW ranks first because the unit of work is enormous and legible: a 200-mile line can cross 1,000+ properties, each needing a negotiated easement and clean title — landmancareer.com.

Clinical-trial amendments carry the hardest cost numbers in the set — $141k–$535k per substantial amendment, 260-day implementation, 76% of trials needing at least one — but both evidence rows come from one vendor, Kitsa, so treat the figures as vendor-cited Tufts CSDD data — kitsa.ai.

The semiconductor idea has the only peer-reviewed evidence in the set: qualification-cycle mechanics from an IOP engineering paper and excursion root-cause economics from IEEE — iopscience.iop.org.

Ideas 7–10 sit lower on whitespace by design: the filing evidence, for example, is a pet-insurance vendor pitching exactly this agent, which proves demand but also proves company — go upmarket to complex commercial lines — insurnest.com.

“Whitespace” here means room for the narrowly defined agentic system-of-action, not an absence of adjacent software, consultants, BPOs or incumbents. Across all ten: integrate with systems of record, price around completed high-value workflows or projects rather than seats, keep humans at legal and safety gates, and expose citations, uncertainty and immutable audit logs.

The evidence rows

Two selected rows per idea. Quality flags: primary/academic (peer-reviewed), reference (association, encyclopedic or legal reference), vendor/market (a vendor or market-research source with an interest in the problem) — do not read vendor claims as settled fact.

#	Idea	Quantified evidence	Quality	Source

Method: 20 evidence rows (two per idea) gathered for this follow-up, from 19 distinct URLs across 17 hosts; no URL supplies more than 10% of rows. Each row carries a workflow, documented pain, quantified evidence, buyer and source link. Pain and whitespace scores on the chart are founder/editorial judgments on a 10- and 5-point scale; ACV and TAM are founder estimates, not source-reported. Full pain narratives, wedges and buyer detail were trimmed for space; quantified evidence is excerpted in the table. The original five ideas from the earlier report are excluded here.

This report was generated automatically by Keenable SELECT at a user's request, from publicly available web sources linked herein. Keenable does not review, verify, or endorse its contents and makes no representation as to accuracy, completeness, or timeliness; AI-based extraction may contain errors. Nothing in this report is investment, legal, financial, or other professional advice. All trademarks and referenced content remain the property of their respective owners; no affiliation or endorsement is implied. To report an error, rights concern, or request removal: legal@keenable.ai.